BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Opperbas Holding N.V. In Breakthrough Clinical Study


10/19/2005 5:11:34 PM

BRUSSELS, Belgium and STOCKHOLM, Sweden, May 28 /PRNewswire/ -- Opperbas Holding B.V. is conducting a phase II clinical trial using its proprietary PEGylated liposomes to prolong the half-life and hemostatic efficacy of recombinant factor VIII, a protein used to treat haemophilia A, a technology developed for Opperbas by the Israeli-based Omri Laboratories Ltd. research company. The delivery technology showed very encouraging results in the phase I/II trial completed last year.

Hemophilia A is currently treated by up to three weekly infusions of FVIII, a protein that is lacking or defective in the affected patients. Opperbas' technology as developed by Omri, carries the potential of reducing the number of infusions to a third of what is presently used while retaining clinical efficacy. This may lead to a major improvement in patient convenience and treatment modality, enabling more patients to use prophylactic treatment and preventing painful and disabling bleeding episodes.

-"We are very pleased with the outcomes so far" - says Dr. Jack Spira, Medical Director . "Our technology has shown to be very promising and we are currently looking at other diseases in which a similar approach can be utilized to enhance the efficacy of protein/peptide drugs".

-"Our goal is to out-license this first indication to one of the major haemophilia pharmaceutical companies and to further develop our technology in similar or other medical indications"- comments Robert Taub founder of the company

ABOUT THE TECHNOLOGY

Opperbas developed a novel patented "platform" technology for the prolongation of protein and peptide half-life and efficacy by formulation with proprietary PEGylated liposomes. The proteins bind non-covalently but with high affinity in a specific mode with the external surface of liposomes without losing their activity. In vivo experiments with several proteins indicate that the half-life and biological efficacy of liposome-formulated proteins are significantly prolonged.

Opperbas is developing near-term pharmaceutical products. Its lead product is an improved product based on Factor VIII with a novel liposome formulation for the treatment of haemophilia A.

ABOUT OPPERBAS HOLDING B.V and OMRI LABORATORIES LTD.

Opperbas Holding N.V., established in 1992, develops delivery technologies. Omri Laboratories Ltd. is a biopharmaceutical company located in the Weizmann Science Park, Rehovot, Israel. The company focuses on the development of PEGylated liposomes as a delivery vehicle for factor VIII (FVIII) and other short half-life proteins/peptides.

Opperbas Holding B.V.

CONTACT: Dr. Jack Spira, tel: +46-708-850-474, Mr. Robert Taub, tel:+32-2-359-91-25. http://www.omrilaboratories.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->